Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. Azd-9291
2. Azd-9291 Mesylate
3. Azd9291
4. Azd9291 Mesylate
5. Mereletinib
6. Mereletinib Mesilate
7. Mereletinib Mesylate
8. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide
9. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide Methanesulfonate (1:1)
10. Osimertinib
11. Osimertinib Mesilate
12. Tagrisso
1. 1421373-66-1
2. Azd-9291 Mesylate
3. Azd9291 Mesylate
4. Azd-9291 (mesylate)
5. Mereletinib Mesylate
6. Tagrisso
7. Osimertinib Mesilate
8. Mereletinib Mesilate
9. Osimertinib Mesylate [usan]
10. Rdl94r2a16
11. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic Acid
12. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide Methanesulfonate
13. Osimertinib Mesilate (jan)
14. Osimertinib Mesylate (usan)
15. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, Methanesulfonate (1:1)
16. Osimertinib Mesilate [jan]
17. 2-propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, Compd. With Methanesulfonate (1:2)
18. Unii-rdl94r2a16
19. Tagrisso (tn)
20. Osimertinib Monomesylate
21. Azd 9291 Mesylate
22. Osimertinib Methanesulfonate
23. Amy226
24. Chembl3545063
25. Schembl14661152
26. Chebi:90948
27. Osimertinib Mesylate [mi]
28. Dtxsid101027822
29. Bcp09934
30. Ex-a1577
31. Hy-15772a
32. Mfcd28137994
33. Osimertinib Mesilate [who-dd]
34. Akos026673944
35. Ds-9913
36. Sb22953
37. Ac-29022
38. Da-35303
39. Osimertinib Mesylate [orange Book]
40. Azd-9291 Mesylate (osimertinibmereletinib)
41. Ft-0699962
42. S5078
43. D10766
44. Q27162942
45. Azd9291 Ms Salt, Osimertinib Ms Salt; Mereletinib Ms Salt
46. N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide Methanesulfonate
47. N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide Methanesulfonate
1. Osimertinib
Molecular Weight | 595.7 g/mol |
---|---|
Molecular Formula | C29H37N7O5S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 10 |
Exact Mass | 595.25768848 g/mol |
Monoisotopic Mass | 595.25768848 g/mol |
Topological Polar Surface Area | 150 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 845 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
TAGRISSO as monotherapy is indicated for:
-the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
- the first-line treatment of adult patients NSCLC with activating EGFR mutations.
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
TAGRISSO as monotherapy is indicated for:
- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01XE
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...
About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Baran Chemical and Pharmaceutical Company operates as part of the DAKPHA Holding conglomerate. This conglomerate, driven by dedicated experts and state-of-the-art technology, is de...
About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : Yes
TE Code :
Brand Name : TAGRISSO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 40MG BASE
Approval Date : 2015-11-13
Application Number : 208065
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : TAGRISSO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 80MG BASE
Approval Date : 2015-11-13
Application Number : 208065
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD :
TE Code :
Brand Name : OSIMERTINIB MESYLATE
Dosage Form : TABLET;ORAL
Dosage Strength : 40MG
Approval Date :
Application Number : 214263
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : OSIMERTINIB MESYLATE
Dosage Form : TABLET;ORAL
Dosage Strength : 80MG
Approval Date :
Application Number : 214263
RX/OTC/DISCN :
RLD :
TE Code :
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Regulatory Info :
Registration Country : Hungary
Brand Name :
Dosage Form : Tablet
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Hungary
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Regulatory Info :
Registration Country : Hungary
Brand Name :
Dosage Form : Tablet
Dosage Strength : 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Hungary
Regulatory Info :
Registration Country : Sweden
Brand Name : TAGRISSO
Dosage Form : FILM COATED PILL
Dosage Strength : 80 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : TAGRISSO
Dosage Form : FILM COATED PILL
Dosage Strength : 40 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Tagrisso
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 40 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Tagrisso
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 80 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Tagrisso
Dosage Form : Tabl
Dosage Strength : 40mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Tagrisso
Dosage Form : Tabl
Dosage Strength : 80mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : Prescription
Registration Country : Canada
OSIMERTINIB (OSIMERTINIB MESYLATE)
Brand Name : TAGRISSO
Dosage Form : TABLET
Dosage Strength : 80MG
Packaging : 30
Approval Date :
Application Number : 2456222
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
OSIMERTINIB (OSIMERTINIB MESYLATE)
Brand Name : TAGRISSO
Dosage Form : TABLET
Dosage Strength : 40MG
Packaging : 30
Approval Date :
Application Number : 2456214
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Iran
Brand Name : Mertisso
Dosage Form : Film Coated Tablet
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 40MG
Brand Name : Mertisso
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Mertisso
Dosage Form : Film Coated Tablet
Dosage Strength : 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 80MG
Brand Name : Mertisso
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Turkey
Brand Name :
Dosage Form : Tablet
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 40MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Turkey
Regulatory Info :
Registration Country : Turkey
Brand Name :
Dosage Form : Tablet
Dosage Strength : 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 80MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Turkey
https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-sept-2024-bms-wins-landmark-fda-approval-for-schizophrenia-med-sanofi-s-dupixent-okayed-for-copd
29 May 2025
// EXPRESSPHARMA
https://www.expresspharma.in/astrazeneca-india-gets-cdsco-approval-for-additional-indication-for-osimertinib-in-unresectable-egfr-mutated-lung-cancer/
09 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/major-cost-savings-on-top-cancer-drugs-with-india-approved-alternatives-302424081.html
27 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-outperforms-osimertinib-with-a-significant-and-unprecedented-overall-survival-benefit-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-302412036.html
25 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250325308922/en/New-study-results-reinforce-TAGRISSO-osimertinib-as-the-backbone-therapy-for-EGFR-mutated-lung-cancer-across-stages-and-settings
08 Jan 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/after-key-win-over-astrazenecas-tagrisso-jj-touts-rybrevant-lazcluze-combo-new-standard-care
01 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/02/3003295/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-ORPATHYS-and-TAGRISSO-Combination-in-Lung-Cancer-Patients-with-MET-amplification-After-Progression-on-Fir.html
Global Sales Information
Company :
Osimertinib Mesylate
Drug Cost (USD) : 1,081,280,466
Year : 2022
Prescribers : 8629
Prescriptions : 64678
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 913,265,970
Year : 2021
Prescribers : 7780
Prescriptions : 56038
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 793,479,172
Year : 2020
Prescribers : 7016
Prescriptions : 49761
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 640,665,670
Year : 2019
Prescribers : 6471
Prescriptions : 41212
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 387,940,690
Year : 2018
Prescribers : 4586
Prescriptions : 25308
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 189,639,073
Year : 2017
Prescribers : 2321
Prescriptions : 12787
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 125,850,146
Year : 2016
Prescribers : 1559
Prescriptions : 9143
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 4,670,268
Year : 2015
Prescribers : 263
Prescriptions : 351
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 40 mg
Price Per Pack (Euro) : 7,767.21
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 80 mg
Price Per Pack (Euro) : 7,767.21
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Tabl
Dosage Strength : 40mg
Price Per Pack (Euro) : 5192.59
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Tabl
Dosage Strength : 80mg
Price Per Pack (Euro) : 5192.59
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 4,328
2019 Revenue in Millions : 3,189
Growth (%) : 36
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 5,015
2020 Revenue in Millions : 4,328
Growth (%) : 16
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 5,444
2021 Revenue in Millions : 5,015
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 5,799
2022 Revenue in Millions : 5,444
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 6,580
2023 Revenue in Millions : 5,799
Growth (%) : 13
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 19
Growth (%) : New Launch
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 955
2016 Revenue in Millions : 423
Growth (%) : 126
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,860
2017 Revenue in Millions : 955
Growth (%) : 95%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 423
2015 Revenue in Millions : 19
Growth (%) : 2,126
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 3,189
2018 Revenue in Millions : 1,860
Growth (%) : 71
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
92
PharmaCompass offers a list of Osimertinib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier.
PharmaCompass also assists you with knowing the Osimertinib Mesylate API Price utilized in the formulation of products. Osimertinib Mesylate API Price is not always fixed or binding as the Osimertinib Mesylate Price is obtained through a variety of data sources. The Osimertinib Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A TAGRISSO manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of TAGRISSO, including repackagers and relabelers. The FDA regulates TAGRISSO manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. TAGRISSO API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of TAGRISSO manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A TAGRISSO supplier is an individual or a company that provides TAGRISSO active pharmaceutical ingredient (API) or TAGRISSO finished formulations upon request. The TAGRISSO suppliers may include TAGRISSO API manufacturers, exporters, distributors and traders.
click here to find a list of TAGRISSO suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A TAGRISSO DMF (Drug Master File) is a document detailing the whole manufacturing process of TAGRISSO active pharmaceutical ingredient (API) in detail. Different forms of TAGRISSO DMFs exist exist since differing nations have different regulations, such as TAGRISSO USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A TAGRISSO DMF submitted to regulatory agencies in the US is known as a USDMF. TAGRISSO USDMF includes data on TAGRISSO's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The TAGRISSO USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of TAGRISSO suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a TAGRISSO Drug Master File in Korea (TAGRISSO KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of TAGRISSO. The MFDS reviews the TAGRISSO KDMF as part of the drug registration process and uses the information provided in the TAGRISSO KDMF to evaluate the safety and efficacy of the drug.
After submitting a TAGRISSO KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their TAGRISSO API can apply through the Korea Drug Master File (KDMF).
click here to find a list of TAGRISSO suppliers with KDMF on PharmaCompass.
A TAGRISSO written confirmation (TAGRISSO WC) is an official document issued by a regulatory agency to a TAGRISSO manufacturer, verifying that the manufacturing facility of a TAGRISSO active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting TAGRISSO APIs or TAGRISSO finished pharmaceutical products to another nation, regulatory agencies frequently require a TAGRISSO WC (written confirmation) as part of the regulatory process.
click here to find a list of TAGRISSO suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing TAGRISSO as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for TAGRISSO API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture TAGRISSO as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain TAGRISSO and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a TAGRISSO NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of TAGRISSO suppliers with NDC on PharmaCompass.
TAGRISSO Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of TAGRISSO GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right TAGRISSO GMP manufacturer or TAGRISSO GMP API supplier for your needs.
A TAGRISSO CoA (Certificate of Analysis) is a formal document that attests to TAGRISSO's compliance with TAGRISSO specifications and serves as a tool for batch-level quality control.
TAGRISSO CoA mostly includes findings from lab analyses of a specific batch. For each TAGRISSO CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
TAGRISSO may be tested according to a variety of international standards, such as European Pharmacopoeia (TAGRISSO EP), TAGRISSO JP (Japanese Pharmacopeia) and the US Pharmacopoeia (TAGRISSO USP).